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Summary Multidrug resistance (MDR) in tumour cells is often caused bv the overexpression of the plasma
membrane drug transporter P-glycuprutein (P-gp) or the recently discosered multidrug resistance-associated
protein (MRP). In this studs we insvestigated the specificity and sensitivity of the fluorescent probes rhodamine
123 (R123). daunorubicin (DNR) and calcein acetoxymethvl ester (calcein-AM) in order to detect the function
of the drug transporters P-gp and MRP. using flow cytometrv. The effects of modulators on the accumulation
and retention of these probes were compared in seseral pairs of sensitise and P-gp- as w-ell as MRP-
oserexpressing cell lines. R123. in combination with the modulator PSC833. provided the most sensitise test
for detecting P-gp-mediated resistance. Moreoser. in a 60 min drug accumulation assay RI23 can be regarded
as a P-p-specific probe. since R123 is not ver- efficiently effluxed bv MRP. In contrast to R123. a 60 mm
DNR or calcein-AM accumulation test could be used to detect MRP-mediated resistance The MRP-specific
modulator genistein could be used in combination with DNR. but not w-ith calcein-AM. Vincristine (VCR)
can be used to increase the cellular uptake of calcein-AM in MDR cells. but is not specific for MRP Thus.
although the combination of DNR with genistein appeared to be as sensitive as the combination of
calcein-AM with VCR. the former mav be used to probe specific MRP activity wshereas the latter provides a
combined (P-gp + MRP) functional MDR parameter. With these functional assavs the role and relatise
importance of P-p and MRP can be studied in. for example. haematological malignancies
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Resistance to chemotherapy. whether it is intrinsic or
acquired. is a major cause of failure in the curative treatment
of haematological malignancies. Among the most active anti-
cancer agents used in the treatment of haematological malig-
nancies are some natural toxin-derived drugs. such as the
anthracycline daunorubicin (DNR). the epipodophyllotoxin
etoposide (VP-16) and the yinca alkaloid vincristine (VCR).
Development of cross-resistance to these structurally and
functionally unrelated drugs is called multidrug resistance
(MDR). One type of MDR is caused by the overexpression
of a plasma membrane protein. P-glycoprotein (P-gp). the
product of the .DR1 gene (Endicott and Ling. 1989). P-gp
functions as an ATP-dependent drug efflux pump. which
results in lower intracellular drug concentrations and, hence.
in drug resistance (Bradley et al.. 1988: Broxterman and
Pinedo, 1991). In some haematological malignancies, such as
acute myeloid leukaemias. non-Hodgkin's lymphomas and
multiple myelomas. P-gp expression appears to be a poor
prognostic factor which might predict refractonrness (Grogan
et al.. 1993). In vitro. MDR can be circumvented by many
relatively non-cvtotoxic agents. such as calcium channel
blockers and cyclosporins (Nooter et al.. 1990: Miller et al..
1991). Therefore. the possibility of reversing MDR in the
clinic has attracted considerable interest.
In addition to P-gp-mediated MDR. a number of in vitro
drug-selected tumour cell lines which do not contain P-gp but
nevertheless show the MDR phenotype have been described
(Kuiper et al.. 1990: Versantsoort et al.. 1992). Several, but
not all. of these non-P-gp MDR cell lines show overexpres-
sion of the gene encoding the multidrug resistance-associated
protein (MRRP). which was recently cloned bv Cole et al.
(1992) from the non-P-gp MDR small-cell lung cancer cell
line H69AR. MRP is a 180-195 kDa membrane glvcoprotein
which, like P-gp. belongs to the ATP-binding cassette (ABC)
superfamilv of membrane transport proteins (Higgins. 1992).
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Gene transfection studies have demonstrated that MRP acts
as a plasma membrane drug efflux pump and that MfRP
overexpression increases resistance to a w-ide spectrum of
natural product drugs (Grant et al.. 1994: Zaman et al.. 1994:
Broxterman and Versantvoort. 1995).
Detection and characterisation of resistant cells in clinical
tumour samples could become an important diagnostic
parameter in clinical practice. Detection of MDR is mostly
performed by using gene-specific probes to detect mRNA
(overexpression or monoclonal antibodies to detect the cor-
responding proteins (Fojo et al.. 1987: Van der Valk et al..
1990). However. since MDR is caused by increased drug
transport out of the cell. the best wsay of measuring would be
to determine the free intracellular drug concentration. By
measuring the drug accumulation in the cells. interpretation
problems resulting from differences in post-translational
modifications of the pump proteins (Center. 1985) and
differences in passive drug uptake through the plasma mem-
brane (Spoelstra et al.. 1992) can be avoided. An additional
important advantage of a functional assay is that it can
determine if the resistance can be modulated by resistance
modifiers. In the case of modulation it may be considered to
administer modifiers in conjunction swith chemotherapy to
the patient.
Flow cytometry is a readily applicable technique to assay
MDR in leukaemias because several highly fluorescent
molecules appear to be substrates for P-gp. The fluorescent
probes rhodarmine 123 (R123: Lampidis et al.. 1985).
daunorubicin (DNR: van Acker et al.. 1993) and calcein
acetoxymethyl ester (calcein-AM: Holl6 et al.. 1994) have
been applied for P-gp detection usinz flow cytometrm. To
date. there are no reports in which the function of the novel
MRP protein in leukaemias is assessed. Since MRP mRNA
is expressed in leukaemias to a widelv different extent (Burzer
et al.. 1994: Schuurhuis et al.. 1995). it swill be important to
studv the functional effect of this protein in leukaemias.
Therefore we investigated the specificity. and sensitivity of
fluorescent probes for detection of P-gp and MRP-mediated
MDR. We compared different fluorescent probes by measur-
ing the effect of modulators on their accumulation and
retention in several drug-sensitive and P-gp- as well as MRP-
mediated resistant cell lines using flow cytometry. Cell linesPigpand MP detcbn byfiw cyluiby
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with a low resistance factor are included to test the sensitivity
of the detection method, since it is likely that low resistance
is important in clinical material (Schuurhuis et al., 1995). In
this report we present the results of experiments which com-
pare daunorubicin. rhodamine and calcein-AM in P-gp and
MRP MDR cells.
Materials and methods
Cell lines
The human epidermoid carcinoma cell line KB3-1 and its
P-gp MDR sublines KB8 and KB8-5 [resistance factor (RF)
for DNR about 2 and 5 respectively] were obtained from Dr
I Roninson (KB3-1 and KB8) and from ATCC, Rockville.
MD, USA (KB8-5). The non-small-cell lung cancer cell line
SW-1573 and its non-P-gp MDR subline SW-1573 2R120
(RFDNIR = 4) have been descnrbed previously (Kuiper et al..
1990). The S1(MRP) (RFDNR = 3.2) subline was obtained by
transfection of SW-1573 (SI) cells wtih an expression vector
containing MRP cDNA and a neomycin resistance gene,
followed by selection with geneticin (Zaman et al., 1994). All
the cell lines were cultured in Dulbecco's minimal essential
medium (MEM) (Flow Labs. Irvine, UK) supplemented with
7.5% heat-inactivated fetal calf serum (FCS) (Gibco Europe.
Paisley. UK). The human acute myelocytic leukaemia cell
line HL60 and its MRP-overexpressing subline HL60 ADR
(RFDox= 80) were obtained from Dr M Center (McGrath et
al., 1989). The human small-cell lung cancer cell line GLC4
and its MRP-overexpressing sublines GLC4-ADR,
(RFDNR = 1.4). GLC4-ADRp. (RFDNR = 6.3) and GLC4-
ADRj_% (RFDNR = 58) have been characterised previously
(Zijlstra et al., 1987; Versantvoort et al., 1995a). The GLC4
and HL60 and their sublines were cultured in RPMI-1640
(Flow Labs) supplemented with 10% FCS. All the resistant
cells were cultured in the presence of selecting drug until
2-10 days before the experiments were performed. The cell
lines were mycoplasma free, as was regularly tested with the
Mycoplasma TC kit (Gen-Probe. San Diego. CA, USA).
Flow cvtometrv
Fluorescence was analysed with a FACScan flow cytometer
(Becton Dickinson Medical Systems. Sharon, MA. USA).
which was equipped with an argon laser. The fluorescence of
10 000 events was logarithmically measured at a laser excita-
tion wavelength of 488 mm. The fluorescence of rhodamine
123, fluorescein isothiocyanate and calcein was collected
through a 530 nm band-pass filter and fluorescence of
daunorubicin was collected through a 575 nm filter. The
logarithmically amplified signals were converted into values
on a linear scale and expressed as relative fluorescence units
(FU). from which the mean fluorescence was calculated.
Drug accumulation and retention
Cells (0.3-0.7 x 106) were incubated for 60 min at 37°C in
2giM DNR (Sigma. St Louis, MO. USA) or 200 ng ml-'
R123 (Sigma) or for 10mmn in 0.5 jLM calcein-AM (Molecular
Probes, Eugene, OR, USA) with or without a modulator in
medium A (growth medium without phenol red and bicar-
bonate buffer, but with 20 mm Hepes) + 10% FCS. PSC833
(Sandoz, Basle, Switzerland) at 2 A&M, 200liM genistein
(Sigma) or 100jim vincristine (Sigma) was used as a
modulator. After the incubation the cells were washed in
ice-cold medium A + 10% FCS. Non-specific binding of the
drugs to the cells was measured by adding ice-cold drug-
containing medium to the cells and washing them im-
mediately.
In order to measure DNR and R123 retention, the cells
were loaded with the drug for 60 mmn. and after washing the
cells were incubated at 37°C in drug-free medium A + 10%
FCS with or without the relevant modulator for 60 min. The
efflux was stopped by centrifuging the cells and adding ice-
cold medium.
P-gp and .RP detection
In order to detect P-gp. viable cells were incubated for 1 h at
room temperature with mouse monoclonal antibody MRK-
16 (10 jig ml-') (kindly provided by Dr T Tsuruo) or a
non-relevant mouse IgG2a (10 fig ml-') (Becton Dickinson).
Cells were washed and for 30 min incubated in the dark with
rabbit anti-mouse fluorescein isothiocyanate (1:100) (Dako-
patts. Copenhagen. Denmark). In order to detect MRP. cells
were permeabilised in 10% (v v) Lysing solution G (Becton
Dickinson) for Omin and then incubated for 1 h at room
temperature with rat monoclonal antibody MRPrl (1.7jig
ml-') or a non-specific rat monoclonal antibody (provided by
M Flens and G Zaman: Flens et al.. 1994). Antibody binding
was detected with rabbit anti-rat fluorescein isothiocyanate
(1:100) (Dakopatts). The mean of the fluorescence of the
MRK16- or MRP-labelled cells was divided by the mean of
the fluorescence of the non-relevant antibody-labelled cells.
Flow-through sYstem
The flow-through system has been described in detail
previously (Lankelma et al.. 1990). Basically. a monolayer of
approximately 10 cells attached to a glass chamber (surface
50 cm2. height 0.1 mm) was perfused with 2 ILM DNR in
medium A. The perfusion medium was passed over the cells
at a constant flow of 200jlI min- at 37°C until a steady-state
level was reached. Then a series of pulse injectionsk of
modulators was introduced into the flowing perfusion
medium. causing inhibition of the DNR efflux. which was
measured at the outlet of the flow-through system as a
decrease in the medium fluorescence of DNR. The fluor-
escence of DNR was measured by a fluorescence detector
(type 821-FP. Jasco. Haschioji City. Japan) at excitation
emission wavelengths of 480 nm 560 nm.
Results
P-gpfunctional assays
Standard fluorescent probes for measuring the function of
P-gp by flow cytometry are R123 and DNR (Lampidis et al.,
1985; Van Acker et al., 1993). A more recently investigated
probe for P-gp is calcein-AM (Hollo et al., 1994; Homolya et
al.. 1993). In this study we compared these probes in order to
assess their sensitivity and specificity for P-gp and MRP
detection in accumulation and retention assays. First, we
determined the accumulation ratio (the ratio of the
fluorescence of drugs accumulated in the resistant and sen-
sitive cell line) for these probes and the effect of the P-gp
inhibitor PSC833 on their accumulation in the KB cell lines.
Solubilisation of the cells with SDS after accumulation of the
dyes confirmed that the effect of modulator on calcein and
R123 fluorescence was indeed caused by an increased dye
uptake. This excludes the possibility that the higher calcein
or R123 fluorescence induced by the modulators is due to an
altered intracellular drug distribution, resulting in a higher
fluorescence of cells. In particular, the analysis of a slightly
resistant cell line, such as KB8 (see last column of Table I for
P-gp expression), is cn'tical in these assays, since this low
level of resistance appears to be relevant for leukaemias
(Schuurhuis et al.. 1995). Table I shows that a reduced DNR
accumulation can be detected in KB8 and KB8-5 cells com-
pared with the sensitive parental KB3-1 cells. R123 and
calcein accumulation were reduced in KB8-5, but not in the
KB8 cell line. However, in the KB8 cell line a distinct effect
of the P-gp modulator PSC833 on the R123 accumulation
could be detected, and this effect of PSC833 was greater than
the effect on DNR accumulation. In contrast, P-gp function
in KB8 could not be detected by PSC833 modulation of
calcein-AM uptake. Thus. the combination of PSC833 withPSp9u - ddcia byflw cSmy
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Table I Comparison of different fluorescent probes in P-gp MDR cells
Accunulation ratio Effect ofPSC833
DNR R123 Calcein DNR R123 Calcein P-gp
KB3-1 1 1 1 0.97 ± 0.04 0.97 ± 0.05 0.95 ± 0.07 1.0;1.0
KB8 0.72 0.19 1.04 0.05 1.23 0.19 1.12 0.06a 1.28 0.14a 0.97 0.05 1.4;1.7
KB8-5 0.27± 0.03 0.08 ±O.Olb 0.19±0.06b 3.11 ± 1.18 11.98± 191b 6.74± 1.68b 12.8;12.3
Data are means ± s.d. of at least three independent experiments. Differences were tested for significance using a
Student's t-test: ap<0.05; bP<O.Ol. The acumulation ratio is the basal fluorescence of resistant cells divided by the
fluorescence ofsensitive cells after drug accumulation. Theeffect ofPSC833 (2jM) is the ratio ofdrug accumulation with
PSC833 divided by drug accumulation without PSC833. The amount ofP-gp is calulated by dividing the mean ofthe
fluorescence of the MRK16-labelled cells by the mean ofthe fluorescence ofthe non-relevant antibody-labelled cells (a
ratio of 1.0 means that P-gp is undetectable).
Table II Comparison of R123 accumulation with retention in P-gp MDR cells
Effect ofPSC833 on Effect ofPSC833 on R123 retention
Cell lines R123 acumulation Loaded with PSC Loaded without PSC
KB3-1 0.97 ± 0.05 1.02 ± 0.03 0.97-1.01
KB8 1.28 0.14a 1.09 0.11 1.47 ± 0.42
KB8-5 11.98± 1.91b 1.72 1.97 11.%-15.23
Data are results of two independent experiments or are means ± s.d. of at least
three independent experiments. Differences were tested for significance using a
Student's t-test: aP<0.05; bP<0.01. Data are ratios of R123 fluorescence with
PSC833 (2pM) divided by R123 fluorescence without PSC833.
R123 appeared to be the most sensitive P-gp functional assay
in these cell lines.
It has been suggested that the sensitivity of a functional
assay can be enhanced by measuring drug retention instead
of accumulation (Ross et al., 1993). We therefore compared
these different experimental set-ups with R123 in the KB cell
lines. Figure 1 shows the time course of the R123 accumula-
tion and retention with and without PSC833 in the KB8 cell
line. The relative effect of PSC833 on the accumulation and
retention was somewhat larger when the accumulation and
efflux time respectively were longer (not shown). However, in
order to compare the sensitivity of an accumulation and
retention assay, time points of 60 min were chosen for prac-
tical reasons. Table II shows that no substantial increase in
the sensitivity of the assays was obtained by measuring the
effect of PSC833 on R123 retention, when cells were loaded
without PSC833. However, when cells were loaded with
PSC833 and subsequently effiuxed, the effect of the
modulator was even much smaller than in the accumulation
assay in KB8-5 cells, and in KB8 cells it was hardly detec-
table. In contrast, when cells were loaded with 20pM
verapamil as modulator instead of 2IsM PSC833, no
difference was observed between the effect of modulator on
R123 accumulation and retention (data not shown).
In order to find an explanation for this apparent dis-
crepancy between the effect of the clinically important
modulator PSC833 on R123 accumulation and retention,
KB8-5 cells were loaded with 2 lM DNR in a flow-through
system until steady-state accumulation was reached. Then a
pulse of 25IM verapamil or 2pM PSC833 was injected into
the DNR-containing medium and the dynamic effect of cel-
lular DNR influx by inhibition of P-gp (and DNR efflux
after passage of the modulator) was recorded by measuring
the fluorescence of DNR in the medium at the outlet of the
flow-through system. DNR influx and efflux by cells were
measured by the decrease and increase of the DNR
fluorescence in the medium respectively (Figure 2). This
experiment showed that the efflux of DNR is much more
rapidly restored when verapamil instead of PSC833 is used as
modulator. Apparently, PSC833 remains much longer in the
cells than verapamil, which explains the slight modulator
effects on the DNR efflux (see middle column of Table II).
Therefore, PSC833 is not suitable for loading cells with drugs
intended for subsequent drug efflux studies.
Modulation ofMRP-mediated transport
The previous experiments showed that measuring the
modulation of R123 accumulation by PSC833 is a convenient
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Fugwe 1 Fluorescence of R123 after uptake and efflux in the
KB8 cells. CeUls were loaded with 200 ngml' R123 for 60min
with (- -0- -) and without (- -O- -) 2 uLm PSC833. Retention
of R123 was measured after suspending the cells in R123-free
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Figue 2 The effect of 2)AM PSC833 and 25iLM verapamil on the
steady-state accumulation of 2JLM DNR in the KB8-5 cell line
measured by the flow-through system (for further experimental
detail see Lankelma et al., 1990). The trace shows the decrease
and increase in DNR fluorescence in the medium as a result of
increased (influx) and decreased (efflux) cellular DNR uptake
respectively.
and sensitive functional assay for detecting P-gp activity. In
order to establish whether PSC833 is also an efficient
modulator for MRP, we first compared the effect of PSC833
with genistein, a compound which has been shown to inhibit
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4 -
nP-gp and kW deledin byflowcytx.wry M N Feller etal
546
MRP- but not P-gp-mediated DNR efflux (Versantvoort et
al.. 1993). Table III shows that the effectiveness of PSC833 as
a modulator of DNR accumulation varied among the
different MRP-overexpressing cell lines. PSC833 was an
effective modulator in the MRP-overexpressing HL60/ADR
cells, but had no effect or only a slight effect on the
accumulation of DNR in the other MRP-overexpressing
cells. In conclusion. PSC833 appeared not to be strictly
specific for P-gp, since in certain tumour cells it may also
interact with DNR transport by MRP.
Since PSC833 was not a potent modulator in most MRP
MDR cells. we investigated the use of genistein as a
modulator in order to compare its effect on transport of
DNR, R123 and calcein-AM. However, in preliminary ex-
periments we found that genistein decreased the fluorescence
of calcein as well as of R123 in sensitive cells. Because of this
interaction. which was apparently unrelated to the presence
of any drug efflux pump, genistein could not be used in
combination with R123 or calcein-AM. Therefore, for R123
and calcein-AM we decided to use VCR as a modulator.
since it has been shown previously that it modulates P-gp- as
well as MRP-mediated drug efflux (Milder et al., 1994).
overexpressing HL60/ADR cell line, as shown before (Table
III), we tested the combination of R123 and PSC833 in these
cells. However, PSC833 had only a slight effect on R123
accumulation in this cell line. We also tested VCR as a
modulator of R123 accumulation in the transfectant
SI(MRP) and in the sensitive cell line SW-1573, but again a
decrease in the fluorescence of R123 was seen in both cell
lines (data not shown), which suggests a non-specific interac-
tion among these drugs, unrelated to the function of the
MRP efflux pump. In conclusion, R123 appeared to be an
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R123 to probe MRPfunction
The results of the R123 accumulation are summarised in
Table IV. It appears that R123 is not a sensitive probe for
detecting MRP-resistant cells, including the MRP transfec-
tant. In fact, in a 60 min accumulation assay no consistently
decreased R123 accumulation was observed. The GLC4-
ADR150 and the HL60 ADR sublines accumulated even more
R123 than the related parent cell lines. Nor was there an
enhanced efflux of R123 in the GLC4-ADR,50 compared with
the GLC4 parent cell line, as illustrated in Figure 3. Only in
the SW-1573/2R120 and the Sl(MRP) sublines could a small
R123 accumulation defect be detected. Since PSC833 was an
effective modulator of DNR transport in the MRP-
Table M Comparison ofthe effect ofPSC833 and genistein on DNR
accumulation in MRP-overexpressing cells
PSC833 Genistein
SW-1573 1.00 ± 0.09 0.99 0.01
S1(MRP) 1.05 ± 0.04 1.19 0.07a
SW-1573 2R120 1.13 ± 0.06 1.21 0.06b
GLC4 1.02 ± 0.02 1.01 ±0.06
GLC4-ADRI,o 1.05 ± 0.05 2.24 ± 0.36'
HL60 1.04 ± 0.06 1.05 0.05
HL60 ADR 1.53 ± 0.06b 1.61 ± 0.25'
Data are ratios of DNR accumulation with a modulator divided by
DNR accumulation without a modulator. Data are means ± s.d. of at
least three independent experiments. Differences were tested for
significance using a Student's t-test: ap<O0.0;bP5<.Ol.
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Fgre 3 Uptake and retention of R123 in the GLC4 and GLC4-
ADR150 cells. GLC4 (- --- -) and GLC4-ADRI% (- -A--) cells
were loaded for 60 min with 200 ng ml- R123. Retention of
R123 was measured after suspending the GLC4 ( - ) and
GLC4-ADRi,5 (-A-) cells in R123-free medium.
Table V MRP overexpression and the effect of genistein on DNR
accumulation and retention in the GLC4 and resistant sublines
Effect ofgenistein Accumulation MRP
Accumulation Retention ratio expression
GLC4 1.01 0.08 1.12 0.04a 1 1.5;1.6
GLC4-ADR, 1.09 + 0.07 1.19 ± 0.04' 0.88 ± 0.16 1.8;2.0
GLC4-ADRp, 1.35-1.47 1.28-1.36 0.53 ± 0.14 2.1;2.5
GLC4-ADR,50 2.24 ± 0.36a 2.08 ± 0.31' 0.13 ± 0.06b 6.6;8.2
Data are means ± s.d. of three independent experiments. For
accumulation studies cells were accumulated with DNR (2gM) for
60 min with and without genistein. Differences were tested for
significance with Student's t-test: 'P<0.05; bp<0.01. For retention
studies the cells were loaded with DNR for 60 min and then cells were
incubated for another 60 min in DNR-free medium with and without
genistein. The effect of genistein is the ratio of the DNR fluorescence
with genistein and thefluorescencewithoutgenistein. Theaccumulation
ratio is the basal fluorescence of resistant cells divided by the
fluorescence ofsensitive cells afterdrug accumulation. MRPexpression
is calculated by dividing the mean of the fluorescence of the
MRPrl-labelled cells by the mean of the fluorescence of the
non-relevant antibody-labelled cells (a ratio of 1.0 means that MRP is
undetectable).
Table IV Comparison of fluorescent probes in MRP-overexpressing cells
Accumulation ratio Effect ofmodulator MRP
DNR Calcein R123 DNR Calkein expression
SW-1573 1 1 1 0.99 0.01 1.00 0.13 1.8;2.2
SI(MRP) 0.56 0.20 0.44 0.03b 0.85 ± 0.12 1.19 0.07a 1.42 0.14' 3.2;3.1
SW-1573 2R120 0.42+ 004b 0.47+ 004b 0.93 1.21 +0.06b 1 29 +003 3.1:25
GLC4 1 1 1 1.01 0.08 0.86 0.09 1.5;1.5
GLC4-ADR,o 0.13 ± 0.06b 0.15 ± 0.14b 1.72 ± 0.14a 2.24 ± 0.36' 2.36 ± 0.67a 6.6:8.2
HL60 1 1 1 1.05 0.05 0.90 0.06 2.1:2.5
HL60 ADR 0.34-0.49 0.17 ± 0.05b 1.65 1.61 ± 0.25' 4.46 ± 0.63' 8.2;7.4
Data are means ± s.d. of at least three independent experiments. Differences were tested for significance with
Student's t-test: ap<0.05: bp<0.0. The accumulation ratio is the basal fluorescence ofresistant cells divided by the
fluorescence of sensitive cells after drug accumulation. Genistein (200pM) was used as a modulator for DNR
accumulation andVCR (100 LM)was used asamodulatorforthecalceinaccumulation. MRP expressioniscalculated
by dividing the mean of the fluorescence of the MRPrl-labelled cells by the mean of the fluorescence of the
non-relevant antibody-labelled cells (a ratio of 1.0 means that MRP is undetectable). For the SW-1573 series the
negative control was obtained by incubation without a pnrmary antibody.
u-
-A
aPgp and kWdeeion by flow cybmety
N Feiler et al
insensitive probe for detecting MRP function. Therefore, we
only tested the modulator effects systematically on DNR and
calcein accumulation.
DNR and calcein to probe MRPfunction
In contrast to R123, DNR and calcein-AM could be used to
detect MRP-mediated resistance. DNR and calcein-AM
appeared to have similar accumulation defects in all the
MRP-overexpressing cell lines, except in the HL60 'ADR sub-
line (Table IV). In these cells the accumulation defect of
calcein and the effect of the modulator on calcein accumula-
tion were greater than the effect on DNR. Since genistein is a
specific modulator of MRP-mediated transport and cannot
be used together with calcein (see above), the preferred com-
bination for specifically detecting the MRP function is DNR
and gemnstein.
Sensitivity ofMRP detection
In order to analyse the sensitivity of the preferred combina-
tion of DNR and genistein for detecting the MRP function,
DNR accumulation and retention were tested in the GLC4
series of cell lines with increasing MRP expression. Table V
shows that DNR accumulation was progressively decreased
in the cell lines with increasing MRP expression. Also, the
effect of genistein on DNR accumulation and retention was
greater in cells with increasing resistance and MRP expres-
sion. However, the retention assay was not more sensitive
than the accumulation assay. Nor did the method of loading
the cells before efflux. with or without genistein. alter the
effect of genistein on DNR retention (data not shown). From
these data it can be inferred that this assay was not sensitive
enough to distinguish between GLC4 and GLC4-ADR, cells,
which are 1.4-fold resistant to DNR (Versantvoort et al.,
1995a). The GLC4-ADRp, and GLC4-ADR,50 sublines which
are 6.3- and 58-fold resistant to daunorubicin respectively.
could easily be detected. Notably in the 3-fold resistant
SI(MRP) cell line, MRP-related drug resistance could be
detected in the DNR accumulation assay. as shown in Table
IV.
Dicussion
Many fluorescent probes (DNR. DOX, R123. Hoechst
33342. BCECF-AM. calcein-AM, FURA-2-AM, etc.) are
available to detect P-gp-mediated MDR. These probes have
been used to detect P-gp by flow cytometry and laser scan
microscopy (Schuurhuis et al., 1991; Homolya et al., 1993;
Van Acker et al.. 1993), and the function of P-gp has been
characterised in many human tumour cell lines. However.
until now systematic studies into the sensitivity and
specificity of these probes for detecting P-gp activity have not
yet been reported. Moreover, this issue has become more
complicated since it is now recognised that at least one other
drug pump, namely MRP. may be involved in MDR. Both
P-gp- and MRP-overexpressions appear to be important
resistance mechanisms in haematological malignancies (Bur-
ger et al., 1994; Kuss et al.. 1994; Schuurhuis et al.. 1995).
In order to gain more insight into the specificity and
sensitivity of methods of detecting MDR by flow cytometry.
we studied three fluorescent probes, R123, DNR and calcein-
AM, combined with three different modulators. PSC833,
genistein and VCR, in P-gp- and MRP-overexpressing cells.
Each of these combinations has its own merits and draw-
backs, as discussed below. The fluorescent probes were
selected for the following reasons. DNR is a cytotoxic drug
with favourable fluorescent properties used in the treatment
of acute myeloid leukaemia (AML) (Schuurhuis et al.. 1995).
Calcein-AM has been reported to be a good probe for P-gp
because it is a hydrophobic non-fluorescent molecule which
rapidly permeates the plasma membrane of cells. By cleavage
of the ester bonds by intracellular esterases it is transformed
to calcein. which is a highly fluorescent, non-membrane-
permeable free acid. Moreover. since calcein. in contrast to
calcein-AM, is not transported by P-gp. it is well retained by
cells, with a fluorescence which is essentially insensitive to
changes in pH. as well as to changes in Ca-+ or Mg"
concentration (Homolya et al., 1993). R123 is also a sensitive
probe for P-gp, but the accumulation of R123 will be depen-
dent on pH and mitochondrial storage capacity. R123 is not
well retained by cells and some leakage of the probe occurs
upon the transfer of accumulated cells into dye-free medium
at O°C (Holl6 et al.. 1994).
In this study we compared these different fluorescent dyes
by measuring the effect of modulators on their accumulation
in P-gp as well as MRP MDR cells. PSC833. a cyclosporin
analogue, was chosen as a modulator for P-gp because it has
acceptable toxicity when given to patients in concentrations
known to reverse P-gp-mediated drug resistance in vitro.
Interestingly, this study provides evidence that the action of
PSC833 on P-gp-mediated DNR pumping is much longer
lasting than the action of verapamil (Figure 2). presumably
because PSC833 remains longer at the P-gp binding site in
the cells. This might also have relevance for clinical modula-
tion studies. Genistein was chosen as a modulator to detect
MRP function in cells because it has been shown to inhibit
specifically MRP-mediated DNR transport. However.
genistein in the presently used concentration is too toxic for
clinical applications (Versantvoort et al., 1993).
We first found that the R123 PSC833 combination pro-
vided the most sensitive test for detecting P-gp-mediated
MDR. This P-gp functional assay is very sensitive since the
slightly resistant KB8 cell line (RFDNR 2 2) could be detected
by PSC833 modulation. This is despite the fact that the KB8
cell line had no accumulation defect for R123. One possible
explanation is that the number of mitochondria is somewhat
increased in this cell line. Remarkably. no modulation of
calcein accumulation could be detected in the KB8 cell line.
whereas in the KB8-5 cell line calcein appeared to be a more
sensitive probe than DNR. The reason for this discrepancy is
not known. For the time being. when clinical samples are
being tested for P-gp function. we would recommend that
R123 be used in combination with 2tgM PSC833.
Next, we tested these probes in MRP-mediated drug-
resistant cell lines. A remarkable result was that R123. the
most sensitive probe for P-gp. was not a suitable probe for
sensitive detection of MRP-mediated drug resistance in cell
lines. Although MRP-overexpressing cells are resistant to
R123 (Zaman et al.. 1994) and the highly MRP-over-
expressing COR-L23 R cell line showed increased efflux of
R123 (Twentyman et al.. 1994). no accumulation defect was
found in the resistant cell lines GLC4-ADR,1, and HL60
ADR after 60 min incubation with R123. It might be surpris-
ing that we found that R123 accumulation after 60 mn is
higher in some MRP-overexpressing cell lines than in the
parental sensitive cell lines. This may be due to R123 being
trapped in cytosolic vesicles containing MRP, as suggested
by Cole et al. (1992). In addition. in contrast to P-gp. an
accumulation defect for R123 can only be found after a
longer incubation time (Twentyman et al.. 1994). Since there
is evidence that the function of drug pumps in clinical sam-
ples, such as in AML cells. may deteriorate after storage. we
prefer short-term (60 mmn) drug accumulation assays. Under
these conditions R123 cannot be used as a probe for detec-
ting MRP-mediated resistance and therefore R123 can be
regarded as P-gp specific.
Calcein-AM appeared to be an effective probe for MRP-
mediated resistance but the specific MRP modulator
genistein decreased calcein fluorescence in sensitive cells and
could not be used as a modulator. For this reason VCR. a
modulator of P-gp- and MRP-mediated resistance (Mfilder et
al.. 1994). was used to modulate the calcein accumulation in
MRP-resistant cells. A disadvantage of the combination of
calcein-AM and VCR is that MRP-related resistance cannot
be distinguished from P-gp-related resistance. Since the com-
bination of DNR and genistein appeared to be as sensitive as
the combination of calcein-AM and VCR. and since DNR
modulation by genistein is specific for MRP. we prefer the
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combination of DNR and genistein for testing specific MRP-
mediated resistance.
Some data suggested a different spectrum of MRP activity
in the human leukaemia HL60 ADR cells since. in contrast
to the other MRP-overexpressing cells. PSC833 is a potent
modulator of the DNR accumulation, and it also appeared
that calcein-AM is a more effective probe than DNR when
this cell line is compared with the other MRP MDR cell
lines. For this reason. calcein-AM with VCR as modulator
may yet be a very useful alternative for testing leukaemias.
Recent studies have suggested that anti-cancer drugs may
be conjugated in cells and that these conjugates may be the
substrate for the MRP transporter (Jedlitschky et al.. 1994).
Resistance would then depend on the conjugating enzymes as
well as on MRP expression. However, it is important to note
here that all the MRP-overexpressing cells tested had an
accumulation defect for calcein. It has been reported that
P-gp extrudes calcein-AM directly from the plasma cell mem-
brane without entering the cellular cytoplasm and that
calcein is not a probe for P-gp (Homolya et al.. 1993; Hol1o
et al., 1994). If MRP extrudes calcein-AM by a similar
mechanism to P-gp. then our data would suggest that MRP
may extrude hydrophobic drugs in a non-conjugated form
from the plasma membrane compartment. Elucidation of the
mechanism of extrusion by MRP of different classes of drugs
needs more research (Versantvoort et al.. 1995b).
In the GLC4 series the degree of MRP expression was in
accordance with drug resistance (Versantvoort et al.. 1995a)
as well as with the DNR accumulation defect. However, the
SW-1573 sensitive cell line had a relatively high level of
MRP. as detected with the MRPrl antibody. but genistein
had no effect on DNR accumulation. One possible explana-
tion for this apparent discrepancy is that cells had to be
permeabilised before being stained with MRPrl, since
MRPrl is a monoclonal antibody which recognises an inter-
nal epitope (Flens et al.. 1994). Therefore, no distinction
could be made between functional MRP in the plasma cell
membrane and MRP in structures such as the Golgi system
(Flens et al.. 1994). Since MRP staining of the plasma mem-
brane SW-1573 cells was undetectable by immunocytochemis-
try (Flens et al.. 1994). it could well be that this cell line
contains more non-functional MRP than other sensitive cell
lines. In future, monoclonal antibodies directed against outer
epitopes of MRP will clarify this point. Alternatively, a role
of intracellular MRP might be inferred from data on the
MRP-overexpressing cell line H69 AR, which showed an
altered intracellular distribution of doxorubicin but no dox-
orubicin accumulation defect (Cole et al.. 1992). For this
reason we also explore another approach to detect P-gp- as
well as MRP-mediated MDR. by using laser scan microscopy
to detect the effect of modulators on the amount of nuclear
anthracycline fluorescence in relation to P-gp and MRP ex-
pression (Broxterman et al.. 1994; Schuurhuis et al.. 1991).
Preliminary data from these studies show that in AML P-gp-
as well as MRP-mediated MDR is at the level of KB8
resistance (Schuurhuis et al.. 1995).
In conclusion, the present study shows that R123
accumulation in combination with PSC833 is a specific and
sensitive test for detecting low levels of P-gp-mediated resis-
tance, which could be of importance in clinical practice. For
detection of MRP-mediated resistance. R123 did not appear
to be a sensitive probe in a 60 min accumulation assay,
whereas the combination of DNR with genistein was more
sensitive and selective. The use of calcein-AM with an appro-
priate modulator (VCR) may be an alternative. The finding
that the P-gp-inhibitory action of PSC833 lasts longer than
that of verapamil may pertain to the use of PSC833 for
modulating MDR in clinical studies.
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